We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Here, we describe methods for evaluating systemic delivery of miR-7 using a lipidnanoparticle formulation in an animal model.
2
The '069 patent relates to lipidnanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
3
Low drug encapsulation efficiency and burst release are the main drawbacks of lipidnanoparticles.
4
The results after tail iv administration of oridonin and oridonin solid lipidnanoparticles were compared.
5
To solve these problems, lipidnanoparticles containing a cross-linked lipid network were prepared in this study.
6
The concentration-time curves of oridonin and oridonin solid lipidnanoparticles were both fitted to the three-compartment model.
7
Solid lipidnanoparticles were helpful for oridonin to reach a long circulation time and were hopeful to be its novel drug carrier.
8
The physicochemical properties of these lipidnanoparticles such as average diameter, drug loading, drug encapsulation efficiency and in vitro drug release were investigated.